What Is 5-Amino-1MQ? Definition and What Research Reports

Plain definition

5-Amino-1MQ is the common shorthand for 5-amino-1-methylquinolinium, a small synthetic chemical compound that has been investigated in laboratory research as a blocker (inhibitor) of an enzyme called nicotinamide N-methyltransferase, usually abbreviated NNMT. In plain terms: cells use a molecule called nicotinamide to help build NAD+, a coenzyme central to energy metabolism. NNMT chemically tags nicotinamide with a methyl group, sending it toward disposal instead. Compounds in the 5-amino-1MQ class were designed to sit in the enzyme's active site and slow that tagging step. Nearly all of the published evidence concerns cells and animals, not approved human therapy.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or any substance discussed in the scientific literature.

What it is in biochemical terms

NNMT transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (MNAM) and S-adenosylhomocysteine. That single reaction connects three systems that researchers study together: the NAD+ salvage pathway, one-carbon and methyl-group metabolism, and the downstream signalling attributed to MNAM. A 2024 review in Archives of Pharmacal Research surveyed this biology and described NNMT as a node linking metabolic pathways to potential therapeutic targeting across metabolic, hepatic, neurological and oncological contexts (PMID 39604638). 5-Amino-1MQ belongs to the family of quinolinium-based nicotinamide mimetics developed as chemical tools to interrogate that node.

Structurally it is a small, charged heteroaromatic molecule with a molecular weight in the low hundreds of daltons. That matters for classification: peptides are chains of amino acids, typically hundreds to thousands of daltons and built from residues; 5-amino-1MQ contains no amino acid residues and no peptide bonds.

Where the term is misused

• "5-Amino-1MQ peptide." This phrasing is common online but is chemically incorrect. The compound is a small molecule, not a peptide, and it does not appear in peptide databases as a sequence.
• Treating NNMT knockdown studies as 5-amino-1MQ studies. Much foundational work used genetic silencing (antisense oligonucleotides or knockout), not this compound. The findings describe the target, not necessarily this molecule.
• Extrapolating from rodent metabolic models to human outcomes. The verified literature summarised below is preclinical; the cited papers did not report approved human indications.
• Assuming one direction of effect. NNMT is context-dependent: papers describe it as harmful in some tissues and disease states and as part of normal physiology elsewhere.

Related terms

What the published literature reports

Metabolic models

The most frequently referenced foundational paper is a 2014 Nature study in which researchers knocked down NNMT in mice using antisense oligonucleotides. The study reported that NNMT knockdown protected against diet-induced obesity in that model, linking the enzyme to adipose tissue and liver energy handling (PMID 24717514). A more recent 2024 report in Diabetes, Obesity & Metabolism examined pharmacological NNMT inhibition and reported mitigation of obesity-related metabolic dysfunction in its experimental model (PMID 39161060). Both are animal or preclinical investigations; neither cited paper described an approved clinical indication or a human dosing regimen.

Vascular and limb function

A 2025 paper in Physiological Reports tested NNMT inhibition in experimental peripheral artery disease and reported improved limb function in the model studied (PMID 41108586). This is an example of the target being explored outside metabolic disease, in ischaemic skeletal muscle biology.

Liver

Researchers reported in the Journal of Hepatology that endoplasmic reticulum (ER) stress upregulated NNMT and that this upregulation contributed to alcohol-related fatty liver development in their experimental system (PMID 32389809). The paper positioned NNMT as a stress-responsive enzyme rather than a fixed housekeeping activity.

Tumour biology and immunity

Several papers describe NNMT as elevated or functionally important in cancer. A 2023 Hepatology study reported that NNMT promoted M2 macrophage polarization via IL6 and myeloid-derived suppressor cell conversion via GM-CSF in gallbladder carcinoma (PMID 36633260). A 2025 Molecular Cancer paper reported that NNMT promoted acquired EGFR-TKI resistance in non-small cell lung cancer through EGR1- and lactate-mediated positive feedback loops (PMID 40089784). In 2025, a Nature study reported that NNMT inhibition in cancer-associated fibroblasts restored antitumour immunity in its models (PMID 40702186). Collectively, these reports explain why NNMT inhibitors are studied as oncology tool compounds, not only as metabolic ones.

Safety and Adverse Events: What Studies Report

Among the verified papers cited here, none was a human safety or tolerability trial of 5-amino-1MQ, and none reported a human adverse-event profile for the compound. What the literature does provide is mechanistic context that is relevant to how researchers frame risk: the 2024 review noted that NNMT sits within methyl-group and NAD+ metabolism, so modulating it has the potential to influence SAM-dependent methylation reactions broadly (PMID 39604638). The alcohol-related fatty liver work showed that NNMT expression itself changes under cellular stress (PMID 32389809), and the tumour-immunity work showed that the same enzyme influences immune cell behaviour (PMID 36633260, PMID 40702186). Readers evaluating claims should note the absence of published controlled human safety data in this evidence set.

Regulatory framing

5-Amino-1MQ is not an approved drug product in the United States and does not appear in the cited literature as an approved therapy for obesity, metabolic disease, cancer or any other indication. In practice the compound is encountered as a research chemical, and material described as "research use only" is, by definition, not evaluated or authorised for human administration. Because it is a small molecule rather than a peptide, it is also not covered by the peptide-specific compounding discussions that apply to substances such as approved peptide drugs. Nothing on this page is legal or medical advice.

How to read claims about this term

1. Check whether the study used the compound or a genetic method. Knockdown results describe the target (PMID 24717514), not a specific inhibitor.
2. Check the species and model. The cited metabolic, vascular and tumour findings were preclinical (PMID 39161060, PMID 41108586).
3. Check the tissue. NNMT biology differs between adipose tissue, liver, stroma and immune compartments (PMID 39604638).
4. Separate mechanism from outcome. A reported change in an enzyme or pathway is not the same as a reported clinical benefit.

References

• Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (Nature, 2014)
• Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction (Diabetes, Obesity & Metabolism, 2024)
• Nicotinamide N-methyltransferase inhibition improves limb function in experimental peripheral artery disease (Physiological Reports, 2025)
• ER stress-induced upregulation of NNMT contributes to alcohol-related fatty liver development (Journal of Hepatology, 2020)
• Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma (Hepatology, 2023)
• NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer (Molecular Cancer, 2025)
• NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity (Nature, 2025)
• Exploring NNMT: from metabolic pathways to therapeutic targets (Archives of Pharmacal Research, 2024)